Zacks Research Issues Positive Outlook for Amarin Earnings

Amarin Co. plc (NASDAQ:AMRN - Free Report) - Equities researchers at Zacks Research upped their Q1 2025 EPS estimates for Amarin in a research note issued to investors on Thursday, April 24th. Zacks Research analyst R. Department now forecasts that the biopharmaceutical company will earn ($1.23) per share for the quarter, up from their prior estimate of ($1.40). The consensus estimate for Amarin's current full-year earnings is ($0.15) per share. Zacks Research also issued estimates for Amarin's Q2 2025 earnings at ($1.12) EPS, Q3 2025 earnings at ($1.25) EPS, Q4 2025 earnings at ($2.23) EPS, FY2025 earnings at ($5.84) EPS, Q1 2026 earnings at ($0.97) EPS, Q2 2026 earnings at ($1.05) EPS, Q3 2026 earnings at ($1.38) EPS, Q4 2026 earnings at ($1.72) EPS and FY2026 earnings at ($5.11) EPS.

Other research analysts have also issued reports about the company. StockNews.com initiated coverage on Amarin in a research report on Wednesday, April 16th. They issued a "sell" rating on the stock. The Goldman Sachs Group cut their target price on shares of Amarin from $20.00 to $7.00 and set a "sell" rating on the stock in a report on Thursday, April 17th.

Amarin Trading Up 0.6 %

AMRN stock traded up $0.06 during trading on Monday, hitting $11.04. 20,026 shares of the stock traded hands, compared to its average volume of 73,606. The stock has a market cap of $226.78 million, a price-to-earnings ratio of -121.21 and a beta of 1.38. Amarin has a one year low of $7.08 and a one year high of $20.60. The company has a 50 day simple moving average of $9.53 and a 200 day simple moving average of $10.36.

Amarin (NASDAQ:AMRN - Get Free Report) last posted its quarterly earnings data on Wednesday, March 12th. The biopharmaceutical company reported ($2.40) earnings per share for the quarter, missing the consensus estimate of ($1.20) by ($1.20). Amarin had a negative net margin of 16.33% and a negative return on equity of 7.22%. The business had revenue of $62.31 million during the quarter, compared to the consensus estimate of $32.37 million.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of AMRN. Arkfeld Wealth Strategies L.L.C. boosted its stake in shares of Amarin by 52.6% during the 4th quarter. Arkfeld Wealth Strategies L.L.C. now owns 58,000 shares of the biopharmaceutical company's stock worth $30,000 after buying an additional 20,000 shares during the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS acquired a new position in shares of Amarin during the 4th quarter worth approximately $36,000. Generation Capital Management LLC bought a new stake in shares of Amarin during the 4th quarter worth approximately $50,000. Stonepine Capital Management LLC acquired a new stake in shares of Amarin in the 4th quarter valued at approximately $55,000. Finally, New York State Common Retirement Fund bought a new position in shares of Amarin in the fourth quarter valued at $68,000. 22.25% of the stock is currently owned by institutional investors.

Amarin Company Profile

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.